Breaking Down Donut Hole Rules: Copays, Discounts, and Caps
The phrase “donut hole” used to describe a gap in Medicare Part D prescription drug coverage has been a common source of confusion and worry for people with Medicare. In plain terms, this article explains what the donut hole meant historically, what changed starting January 1, 2025, and how copays, manufacturer discounts, and the new out-of-pocket caps work today and into 2026. Understanding these rules helps beneficiaries make informed choices during open enrollment and manage prescription costs throughout the year.
What the donut hole was and why the change matters
Historically, the donut hole (coverage gap) was a phase of the standard Medicare Part D benefit in which enrollees temporarily paid a larger share of prescription costs after reaching an initial spending threshold and before qualifying for catastrophic coverage. That structure required tracking multiple thresholds and meant people could face higher out-of-pocket costs mid-year. As part of the Part D redesign under the Inflation Reduction Act, the separate coverage gap was eliminated effective January 1, 2025; Part D now moves beneficiaries from a deductible phase to an extended initial coverage phase that ends when the beneficiary reaches an annual out-of-pocket cap, after which catastrophic-level coverage begins.
Key components of the new Part D structure
Today’s Part D design still has recognizable components: a deductible (if your plan has one), an initial coverage phase determined by plan formularies and negotiated prices, and catastrophic coverage once the annual out-of-pocket (OOP) limit is reached. The most material change is the annual OOP cap: a fixed dollar amount that limits what beneficiaries pay in covered drug costs in a calendar year. Manufacturer discounts and plan-level changes also affect how costs are allocated between manufacturers, plans, the government, and enrollees.
How copays, discounts, and plan responsibilities work now
Manufacturer discounts now operate under a new Manufacturer Discount Program that replaced the old Coverage Gap Discount Program. Under current CMS guidance, manufacturers typically provide a manufacturer-paid discount on certain brand-name drugs during the initial coverage phase and remain involved in providing discounts as part of managing overall Part D spending. Plans and the federal government also share responsibility for costs differently than in the traditional pre-2025 model; some reinsurance and subsidy rules were adjusted so plans have greater upfront liability and the government provides a larger upfront subsidy. These shifts affect how much enrollees pay at the pharmacy before they reach the OOP cap.
Benefits, trade-offs, and practical considerations
The most obvious benefit for beneficiaries is predictability: a calendar-year out-of-pocket cap limits maximum spending on covered Part D drugs. That cap reduces the risk of facing very high drug costs partway through the year and eliminates the need to track multiple gap thresholds. At the same time, plans continue to use formularies, tiered copays, prior authorization, quantity limits, and step therapy to manage utilization and costs, so enrollees still need to check which drugs are covered and what cost-sharing applies. Also, the cap applies to covered Part D drugs only; non-covered drugs, certain over-the-counter items, or drugs covered under Part B or other programs may not count toward the cap.
Recent trends, policy updates, and the local context for 2026
Medicare’s Part D redesign has continued to evolve since enactment. Important dates to remember are January 1, 2025 (when the coverage gap was eliminated for the 2025 benefit year) and annual indexing of the OOP cap. For example, the first-year out-of-pocket cap was set for 2025 and is indexed for inflation; CMS announced an adjusted cap for 2026. Meanwhile, CMS implemented the Manufacturer Discount Program and updated plan and reinsurance calculations so that plan sponsors and manufacturers share costs differently than under the old coverage-gap model. Because some of these rules are implemented through CMS notices and program instructions, beneficiaries should review official CMS guidance or their plan materials for local plan-level details each year.
Practical tips to manage prescription costs under the redesigned Part D
1) Review plan formularies and total cost estimates during Medicare Open Enrollment: formularies, tier placement, and negotiated prices still determine most out-of-pocket costs before you hit the cap. 2) Ask your prescriber and pharmacist about therapeutically equivalent generics or lower-cost alternatives and request prior authorization or exception assistance when appropriate. 3) If you have limited income and resources, check whether you qualify for Extra Help (Low-Income Subsidy) — it can dramatically reduce or eliminate cost sharing and counts toward cost limits differently. 4) Keep good records of copays and any third-party payments, because some non‑beneficiary payments may or may not count toward your plan’s OOP tally. 5) If you’re on high-cost specialty drugs, contact your plan early in the year to understand specialty tiers, step therapy rules, and any manufacturer-supported programs that may reduce your immediate cash cost.
Summary of the most important numbers and timeline
Two dates and figures are most useful to remember: the coverage gap as a distinct Part D phase ended on January 1, 2025, and the annual out-of-pocket cap that limits beneficiaries’ spending was established beginning with the 2025 benefit year and is indexed annually. That means beneficiaries now move from deductible/initial coverage directly to catastrophic coverage once they reach the OOP limit for the year, rather than entering a separate coverage gap. Because program rules and dollar amounts are updated by CMS, checking official guidance for the applicable calendar year is important.
Quick reference: how 2024 differed from 2025+ for Part D
| Feature | Typical 2024 arrangement (historical) | 2025 and after (current) |
|---|---|---|
| Coverage gap (“donut hole”) | Separate coverage gap phase with 25% or higher cost-sharing depending on drug and year. | Eliminated as a distinct phase beginning Jan 1, 2025; beneficiaries progress to an OOP cap and then catastrophic coverage. |
| Annual out-of-pocket cap | No universal cap on covered Part D drug costs; beneficiaries could continue paying until catastrophic phase thresholds were met. | Cap set for 2025 (initial dollar amount) and indexed; CMS announced the indexed amount for 2026. |
| Manufacturer discounts | Coverage Gap Discount Program provided discounts in the gap (phased out). | Replaced by the Manufacturer Discount Program with new discount and contracting rules. |
| Plan and government cost sharing | Plans had more limited upfront liability; reinsurance covered large post‑catastrophic costs. | Reinsurance and subsidy calculations were adjusted so plans assume more upfront responsibility and government subsidy shifts accordingly. |
Conclusion
In short, the traditional Medicare Part D donut hole is no longer a separate phase: as of January 1, 2025, Part D moved to a structure that caps beneficiary out‑of‑pocket costs in a calendar year and relies on a combination of manufacturer discounts, plan design, and government subsidies to control costs. This reform improves predictability and offers stronger protection against very high drug spending, but it does not eliminate the need to review formularies, understand plan rules, or pursue low‑income programs if you qualify. For personalized guidance, contact your plan, speak with a licensed benefits counselor, or use the official Medicare resources during open enrollment.
Frequently asked questions
- Q: Does the donut hole still exist? A: No. The coverage gap as a distinct phase was eliminated on January 1, 2025; Part D now uses an annual out-of-pocket cap before catastrophic coverage begins.
- Q: How do I know when I reach the out-of-pocket cap? A: Your Part D plan tracks accumulations of qualifying out-of-pocket spending; your plan’s website, explanations of benefits, or customer service can tell you how close you are to the yearly cap.
- Q: Do manufacturer discounts reduce what I pay today at the pharmacy? A: Manufacturer discounts are part of the overall cost allocation. Some discounts may reduce what the plan or government ultimately pays, and others may affect how costs count toward the OOP cap; check plan materials or CMS guidance for specifics about how a particular drug’s payments are counted.
- Q: If I have low income, are there extra protections? A: Yes. The Extra Help (Low-Income Subsidy) program can substantially reduce or eliminate premiums, deductibles, and copays for eligible people. Contact your state Medicaid office or Social Security for eligibility details.
Sources
- CMS — CMS Releases Proposed 2026 Payment Policy Updates for Medicare Advantage and Part D Programs — explains the Part D redesign timeline and the indexed out-of-pocket cap for 2026.
- CMS — CMS Releases 2025 Medicare Part D Bid Information and Announces Premium Stabilization Demonstration — background on the Inflation Reduction Act changes and the initial out-of-pocket cap implementation.
- CMS — Part D Information for Pharmaceutical Manufacturers — details on the Manufacturer Discount Program and implementation materials.
- HealthCare.gov — Medicare prescription drug donut hole (glossary) — plain-language explanation of what changed and how the cap functions.
Disclaimer: This article provides general information about Medicare Part D design and recent policy changes. It is not legal, tax, or individualized medical advice. For plan-specific details, eligibility questions, or decisions about what medication to take, consult your plan documents, a licensed benefits counselor, or a qualified health professional.
This text was generated using a large language model, and select text has been reviewed and moderated for purposes such as readability.
